#precision oncology

2 stories

#ai #anterior #bill golden #breast cancer #business #cdk2 inhibitors #claims #clinical trials #durham #health plan #healthcare #incyclix bio

Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies
Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers.
Dealroom · 1m
Former UnitedHealthcare CEO on AI's Role in Healthcare
Healthcare CEO warns AI could transform claims and payments without disrupting provider-payer relationships.
Newsweek · 1m